{"filing":{"accession_number":"0001104659-26-072930","cik":"0001346830","ticker":"TVRD","company_name":"Tvardi Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"tm2617528d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465926072930/tm2617528d1_8k.htm"},"events":[{"id":5287,"run_id":4634,"accession_number":"0001104659-26-072930","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Tvardi Therapeutics' Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for four proposals: election of three Class II directors (Imran Alibhai, Cynthia Smith, and Sujal Shah), advisory approval of executive compensation, frequency of compensation votes, and ratification of Deloitte \u0026 Touche LLP as independent auditor. All proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.","company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6244,"accession_number":"0001104659-26-072930","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Tvardi Therapeutics' Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for four proposals: election of three Class II directors (Imran Alibhai, Cynthia Smith, and Sujal Shah), advisory approval of executive compensation, frequency of compensation votes, and ratification of Deloitte \u0026 Touche LLP as independent auditor. All proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:08:34.785467+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6244,"accession_number":"0001104659-26-072930","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Tvardi Therapeutics' Annual Meeting of Stockholders held on June 9, 2026. The filing presents voting results for four proposals: election of three Class II directors (Imran Alibhai, Cynthia Smith, and Sujal Shah), advisory approval of executive compensation, frequency of compensation votes, and ratification of Deloitte \u0026 Touche LLP as independent auditor. All proposals passed with substantial majorities, making this a routine but material shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:08:34.785467+00:00","company_name":"Tvardi Therapeutics, Inc.","ticker":"TVRD","filing_date":"2026-06-11"}]}